Preservation of Anemia Control and Weekly ESA Dosage After Conversion from PEG-Epoetin Beta to Darbepoetin Alfa in Adult Hemodialysis Patients: The TRANSFORM Study

INTRODUCTION: There is scant real-world information on switching treatment for anemia associated with chronic kidney disease (CKD) from methoxy polyethylene glycol-epoetin beta (PEG-Epo) to darbepoetin alfa (DA). TRANSFORM was a multi-center, observational study designed to describe the time course...

Descripción completa

Detalles Bibliográficos
Autores principales: Donck, Jan, Gonzalez-Tabares, Lourdes, Chanliau, Jacques, Martin, Heike, Stamatelou, Kyriaki, Manamley, Nick, Farouk, Mourad, Addison, Janet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4245491/
https://www.ncbi.nlm.nih.gov/pubmed/25367412
http://dx.doi.org/10.1007/s12325-014-0161-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4245491/
https://www.ncbi.nlm.nih.gov/pubmed/25367412
http://dx.doi.org/10.1007/s12325-014-0161-5

Ejemplares similares